IL2 and acute myeloid leukemia: At the price of substantial side effects, success was seen in hematological cancers such as multiple myeloma, follicular lymphoma and myeloproliferative disorders, including chronic myeloid leukemia and polycythemia vera (interferons) and acute myeloid leukemia (AML) post allogeneic stem cell transplantation (interleukin-2) [2, 3].